-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Aducanumab (Biogen)
Biogen’s Aducanumab: Possibly the First Viable Drug Treatment of Alzheimer’s Disease? (BBC News)
Summary There were early hopes that the drug Aducanumab (from Biogen) might be able to slow down the build-up of amyloid protein in the brain, but trials were halted in March 2019 due to “disappointing” trial results. Subsequent re-analysis of … Continue reading →
Posted in BBC News, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Aducanumab, Aducanumab (Biogen), Aducanumab: Recombinant Human Monoclonal Antibody, Aβ, Aβ Accumulation, Aβ-Plaques, Aβopathy, Amyloid Beta, Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, Amyloid-Related Imaging Abnormalities-Edema (ARIA-E), Amyloidopathy, Antibody-Based Immunotherapy Against Aβ, ARIA-E Episodes, Beta-Amyloid, Beta-Amyloid Plaques, Biogen, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Side-Effects, Drug Trials Failure Rate, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, Drugs for Treatment of Alzheimer’s Disease, Edema, β-Amyloid (Aβ) Accumulation, β-amyloid Deposition, Monoclonal Antibodies, Neurimmune, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Oedema, Phase 3 EMERGE Study, Phase 3 ENGAGE Study, Slowing of Cognitive Decline, Treatment of Alzheimer's Disease
|
Leave a comment
BBC iWonder Guide: How Close Are We to Stopping Alzheimer’s Disease? (BBC News)
Summary The BBC’s iWonder Guides provide “thought-provoking answers to the questions sparked by everyday life”. This particular collection of brief digestible articles, animations and videos covers: A frightening prospect (epidemiological statistics). How the disease affects your brain cells (an interactive … Continue reading →
Posted in Animal Studies, BBC News, In the News, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Aducanumab, Aducanumab (Biogen), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-Beta Clearance in Mice, Amyloid-Related Imaging Abnormalities (ARIA), Amyloid-Related Imaging Abnormalities-Edema/Effusion (ARIA-E), Anti-Amyloid-β (Aβ) Immunotherapy Trials, BBC Health News, BBC iWonder Guide on Alzheimer's Disease, BBC iWonder Guides, Brain Drain: Brain Glymphatic Transport, Brain Glymphatic System, Clearance of Amyloid Beta Protein, CNS Lymphatic System: Hypothesis Regarding Poor Sleep Patterns and Neuropathology, Dementia Prevalence, Drug Side-Effects, Drug Trials, Glymphatic System, iWonder Guides (BBC), Lifestyle Risk Factors, Misfolded Proteins, Modifiable Risk Factors, Need For Sleep, Neurofibrillary Tangles, Neurofibrillary Tangles (NFTs), Neuronal Loss, Neuropathological Features, Neuropathology, Neuroprotective Lifestyles, Prevention, Prevention Agenda, Prevention Approaches, Prevention of Dementia, Preventive Health, Professor Maiken Nedergaard: University of Copenhagen, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Sleep Duration, Sleep Hygiene, Sleep Patterns, Sleeping Well, Tau Tangles, Therapeutic-Induced ARIA, Treatment Side-Effects: Therapeutic-Induced ARIA, University of Copenhagen
|
Leave a comment
Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)
Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading →
Posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Aducanumab, Aducanumab (Biogen), Aβ40, Aβ42, Amyloid, Amyloid Beta, Amyloid Hypothesis, Amyloid Precursor Protein (APP), Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Amyloidopathy, Anti-Amyloid Therapies, APECS Phase 3 Trial (ClinicalTrials.gov Identifier: NCT01953601), Aspartyl Proteases β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1 or β-Secretase), ß-amyloid, BACE1, BACE1 Inhibitors, Behind the Headlines, Beta-Amyloid, Beta-Amyloid Plaques, Biomarkers, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cleveland Clinic Foundation, Department of Biostatistics: Merck Research Laboratories, Department of Clinical Research: Merck Research Laboratories, Department of Global Chemistry: Merck Research Laboratories, Department of Neuroscience: Merck Research Laboratories, Department of Pharmacokinetics Pharmacodynamics and Drug Metabolism: Merck Research Laboratories, Department of Safety Assessment: Merck Research Laboratories, Department of Translational Medicine: Merck Research Laboratories, EPOCH Phase 2/3 Trial (ClinicalTrials.gov Identifier: NCT01739348), β-Secretase 1 (BACE1), Lerner Research Institute, Merck Research Laboratories, PAREXEL (Glendale USA), Phase III APECS Study, sAPPβ, Science Translational Medicine, Translational Biomarkers Department: Merck Research Laboratories, Translational Neurodegeneration, United States, USA, Verubecestat, Verubecestat: Reduction of CSF Aβ and sAPPβ in Healthy Adults and AD Patients
|
Leave a comment
Early Signs of a Historic Breakthrough in the Treatment of Alzheimer’s Disease? (BBC News / Nature)
Summary Early results, based on small numbers of patients in a Phase I trial, indicate unprecedented progress in the development of a pharmacological treatment of Alzheimer’s Disease. The drug Aducanumab appears to combat (and reverse) the build-up of amyloid protein … Continue reading →
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Scotland, UK, Universal Interest
|
Tagged Aducanumab, Aducanumab (Biogen), Aducanumab: Recombinant Human Monoclonal Antibody, Aβ, Aβ Accumulation, Aβ-Plaques, Aβopathy, Amyloid Beta, Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, Amyloidopathy, Antibody-Based Immunotherapy Against Aβ, BBC Health News, Beta-Amyloid, Beta-Amyloid Plaques, Biogen, Butler Hospital (USA), Centre for Cognitive and Neural Systems at the University of Edinburgh, Clinical Dementia Rating—Sum of Boxes, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Side-Effects, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, Drugs for Treatment of Alzheimer’s Disease, Identification of People At Risk of Dementia, Institute for Regenerative Medicine: University of Zurich, International Collaborations, International Programmes, International Research, Intravenous Infusions of Aducanumab, β-Amyloid (Aβ) Accumulation, β-amyloid Deposition, Mini Mental State Examination (MMSE), Monoclonal Antibodies, Neurimmune (Switzerland), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurofibrillary Tangles, Positron Emission Tomography (PET), Research and Development, Research and Innovation, Research Commitment, Slowing of Cognitive Decline, Susceptibility to Side-Effects of Medication, Switzerland, Treatment of Alzheimer's Disease, University College London, University of Edinburgh, University of Zurich
|
Leave a comment
New Drugs for Dementia (POST Note PN 535)
Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program
|
Leave a comment
